Abner Mason

Closing gaps in care and improving the lives of minority patients through technology-based patient engagement solutions which take into account the cultural and linguistic barriers patients face to understanding the complex world of healthcare.

7Wire, Tufts, Salesforce, DaVita, American Heart Association, Victor Oladipo
Bob Nelsen, Rahul Singhvi, Sc.D., and Pat Yang, Ph.D.

Changing the way complex medicines are made and distributed by leveraging technology innovation to better serve scientific discovery, withstand disruptive events, and reach those in need.

ARCH Venture Partners, GV, 8VC, NEA, leading public investors, five of the largest pharmaceutical companies
Brendan Frey, Ph.D.

Using AI to rapidly accelerate drug discovery and development for rare genetic diseases by predicting development outcomes upfront via proprietary disruptive technology.

SoftBank Vision Fund 2, Fidelity Management, Khosla Ventures, True Ventures, Future Ventures, Alexandria Venture Investments, Amplitude Ventures
Tillman Gerngross, Ph.D., and Leonard Zon, M.D.

Using state of the art antibody discovery and optimization strategies, Amagma selectively inhibits extracellular enzymes that, when overactive, can cause broad inflammatory response.

Amanda French

Safeguarding birth control through robust technology that addresses the pain points and obstacles of effective birth control.

Bolt Capital, AVG
Matthew Stoudt, Josh Sackman, and David Sackman

Fighting to solve the opioid crisis and improve mental health by offering safe virtual reality digital therapeutics to treat acute and chronic pain and other diseases including anxiety and PTSD.

F-Prime Capital, JAZZ Venture Partners, Sway Ventures, GSR Ventures, Cedars-Sinai
Julio Aguirre-Ghiso, Ph.D., Ari Nowacek, M.D., Ph.D., and Alan Rigby, Ph.D.

Developing first-in-class drugs that target dormant disseminated tumor cells (DTCs) to help prevent the recurrence of cancer.

ARCH Venture Partners, Celgene Corporation, Hillhouse Capital, 6 Dimensions Capital, NYC Life Sciences Fund
Francois Kress

Focused on improving mental health through the use of non-invasive neuromodulation devices which stimulate brain pathways and activate the body’s natural relaxation response, built on technology from Harvard Medical School, Rutgers and MIT.

ARCH Venture Partners, True Ventures, M13

“It has been an honor to work alongside the Magnetic Ventures team. The incredible expertise they bring to the table and their willingness to dig in and share not just their knowledge but also their networks, has been the kind of experience you dream of as a Founder. Their passion and support of our mission has challenged us as a company to think bigger and build better solutions for both our clients and the communities we serve.”

Abner Mason

Founder & CEO, ConsejoSano